Baseline Hepamet fibrosis score is associated with type 2 diabetes remission after bariatric surgery

Thumbnail Image

Files

Baseline Hepamet fibrosis.pdf (1.6 MB)
Identifiers
URI: https://hdl.handle.net/11268/17441
DOI: 10.1016/j.soard.2026.05.016

Publication date

2026

Authors

Martínez Montoro, José Ignacio
Pinazo Bandera, José M.
García Serrano, Sara
García Almeida, José Manuel
Ocaña Wilhelmi, Luis

Advisors

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

SDG

goal-3

Metrics

Google Scholar

Research Projects

Organizational Units

Journal Issue

Abstract

Type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) share common pathophysiological mechanisms and exert reciprocal influences on each other. Bariatric surgery (BS) is the most effective treatment for the improvement and resolution of both conditions; however, little is known about the role of MASLD in diabetes remission following BS.

Description

UNESCO Subjects

Sistema endocrino
Enfermedad
Cirugía

Keywords

Bibliographic reference

Martínez-Montoro, J. I., Pinazo-Bandera, J. M., García-Serrano, S., García-Almeida, J. M., Ocaña-Wilhelmi, L., Moreno-Ruiz, F. J., Soler-Humanes, R., Ruiz-Campos, N., Sancho-Marín, R., García-Cortés, M., Muñoz-Garach, A., Fernández-García, J. C., García-Fuentes, E., Tinahones, F. J., & Garrido-Sánchez, L. (2026). Baseline Hepamet fibrosis score is associated with type 2 diabetes remission after bariatric surgery. Surgery for Obesity and Related Diseases, 22(10), 1140-1147. https://doi.org/10.1016/j.soard.2026.05.016
Editor's version
http://doi.org/10.1016/j.soard.2026.05.016

Type of document

journal article

Collections

Área de Ciencias de la Salud
Attribution-NonCommercial-NoDerivatives 4.0 International

La licencia de este ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International